This 2022 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks in 2,539 adults with obesity or overweight with at least one weight-related comorbidity, excluding diabetes. Participants receiving tirzepatide experienced significant, dose-dependent weight reductions: −15.0% with
